Company Description
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally.
The company offers forefoot systems, including gorilla precision MTP plating system, gorilla precision lapidus plating system, phantom lapidus intramedullary nail system, Bun-Yo-Matic lapidus clamp, and precision MIS screw system; and fracture fixation systems comprising gorilla ankle fracture plating system, baby gorilla plating system, monster screw system, monkey bars external fixation system, R3Flex syndesmotic repair system, and phantom fibula nail system.
It also provides flatfoot systems, such as gorilla universal plating system, JAWS great white staple system, monster screw system, grappler suture anchor system, and mister tendon harvester system; ankle replacement system consists of metallic and plastic implant components, as well as ankle fusion plating system and phantom hindfoot nailing system; Charcot systems, including the joust beaming system, gorilla medial column plating system, and monkey rings external fixation system; and orthobiologics products, such as V92 cellular bone matrix, PRESERVE bone wedges, MgNum bone void filler, and BEAST demineralized bone matrix.
The company serves hospitals, ambulatory surgery centers, and health care facilities through a network of sales representatives and stocking distributors.
Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
| Country | United States |
| Founded | 2010 |
| IPO Date | Oct 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 525 |
| CEO | Albert DaCosta |
Contact Details
Address: 14445 Grasslands Drive Englewood, Colorado 80112 United States | |
| Phone | 720-912-1332 |
| Website | paragon28.com |
Stock Details
| Ticker Symbol | FNA |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001531978 |
| CUSIP Number | 69913P105 |
| ISIN Number | US69913P1057 |
| Employer ID | 27-3170186 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Albert DaCosta | Co-Founder, Chairman, President and Chief Executive Officer |
| Robert S. McCormack J.D. | General Counsel and Secretary |
| Matthew Jarboe | Executive Vice President of Sales and Chief Commercial Officer |
| Andrew James Hill | Executive Vice President of Research and Development |
| Chadi Chahine | Chief Financial Officer and Executive Vice President of Supply Chain Operations |
| Matthew Brinckman | Senior Vice President of Strategy and Investor Relations |
| Brendan Shook | Executive Vice President of Marketing and Medical Education |
| Dr. Matthew Millard | Chief Human Resources Officer |
| John Shumaker | Executive Vice President of Sales - U.S. |
| Hans Kestler | Executive Vice President of International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 21, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 21, 2025 | 8-K | Current Report |
| Apr 21, 2025 | 25-NSE | Filing |
| Apr 21, 2025 | 10-K/A | [Amend] Annual report |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | 8-K | Current Report |